Merck & Co., Inc.
MRKNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 7, 2026Score 9/30250% above fair value
$149.52+3.19 (+2.18%)
Close on Oct 30, 2026Market cap $368.89BP/E 119.6Yield 2.19%
Merck Fosamax by Quarter
Fosamax (alendronate, legacy pre-Organon spin-off) — Worldwide reported growth YoY (%) (%)
Merck Fosamax: -18.0% in Q4 2018, down 9.0 pts from a year earlier. No newer figure appears in the documents we track.
Latest, Q4 2018
-18.0%
Period ended Dec 31, 2018
Change on a year earlier
-9.0 pts
-9.0% in Q4 2017
History
5 quarters
Since Q4 2017
Sources
5
Documents cited below
Where the Q4 2018 figure comes from
“|| Fosamax | 50 | 62 | -18 | 1 | (1 | ) | * | 49 | 62 | -21”
Source: Form 8-K (a19-3795_1ex99d1.htm, filed 2019-02-01) ↗
Reported in Form 8-K Table 3 / 3a / 3b Product Sales.
Quarterly history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Fosamax (alendronate, legacy pre-Organon spin-off) — Worldwide reported growth YoY (%) (%) | Year on year | Source |
|---|---|---|---|---|
| Q4 2018 | Dec 31, 2018 | -18.0% | -9.0 pts | Form 8-K (a19-3795_1ex99d1.htm, filed 2019-02-01) ↗ |
| Q3 2018 | Sep 30, 2018 | -16.0% | – | Form 8-K (a18-37128_1ex99d1.htm, filed 2018-10-25) ↗ |
| Q2 2018 | Jun 30, 2018 | -11.0% | – | Form 8-K (a18-17779_1ex99d1.htm, filed 2018-07-27) ↗ |
| Q1 2018 | Mar 31, 2018 | -9.0% | – | Form 8-K (a18-12417_1ex99d1.htm, filed 2018-05-01) ↗ |
| Q4 2017 | Dec 31, 2017 | -9.0% | – | Form 8-K (a18-5152_1ex99d1.htm, filed 2018-02-02) ↗ |
Cite this data
StockData. (2026). Merck Fosamax (%), quarterly Q4 2017–Q4 2018 [Data set]. Compiled from Merck SEC filings and investor materials. https://stockdatahq.com/stocks/mrk/kpis/rev-fosamax-ww-nom-yoy
See every metric in the Merck KPI table. Data updated Oct 26, 2026.